(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 January 2011 (06.01.2011)

PCT

(10) International Publication Number
WO 2011/003065 A2

(51) International Patent Classification:
C07D 487/04 (2006.01) *A61K 31/437* (2006.01)
C07D 403/12 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2010/040906

(22) International Filing Date:
2 July 2010 (02.07.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/222,918 2 July 2009 (02.07.2009) US

(71) Applicant *(for all designated States except US)*: **GENENTECH, INC.** [US/US]; 1 DNA Way, South San Francisco, California 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GIBBONS, Paul** [US/US]; 2792 24th Street, San Francisco, California 94110 (US). **HANAN, Emily** [US/US]; 1904 Woodside Road, Redwood City, California 94061 (US). **LIU, Wendy** [CN/US]; 343 Catamaran Street, Foster City, California 94404 (US). **LYSSIKATOS, Joseph P.** [US/US]; 42 Alta Avenue, Piedmont, California 94611 (US). **MAGNUSON, Steven R.** [CA/US]; 3288 South Bridgepoint Lane, Dublin, California 94568 (US). **MENDONCA, Rohan** [US/US]; 3551 Ballantyne Drive, Pleasanton, California 94588 (US). **PASTOR, Richard** [US/US]; 243 Waller Street, San Francisco, California 94102 (US). **RAWSON, Thomas E.** [US/US]; 140 Hamilton Avenue, Mountain View, California 94043 (US). **SIU, Michael** [US/US]; 454 Chatham Road, Burlingame, California 94010 (US). **ZAK, Mark E.** [CA/US]; 401 South Norfolk Street, #309, San Mateo, California 94401 (US). **ZHOU, Aihe** [US/US]; 1361 Stephen Way, San Jose, California 95129 (US). **ZHU, Bing-Yan** [US/US]; 135 Lois Lane, Palo Alto, California 94303 (US).


(74) Agents: **WALSH, Christopher J.** et al.; Genentech, Inc., 1 DNA Way, MS 49, South San Francisco, California 94080 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS



(I)

(57) Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R^1, R^2 and R^3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.

WO 2011/003065 A2

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*